Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • Advanced therapies
  • Virology
  • Bacteriology
  • Biotherapeutics
  • Analytical sciences
  • Diagnostics
  • A to Z listing
  • Publications
  • Home  /  
  • Science and research  /  
  • Advanced therapies  /  
  • Genomic reference materials  /  
  • Prader Willi and Angelman (WHO)

Prader Willi and Angelman syndromes

Prader Willi (PWS; OMIM #176270) and Angelman (AS; OMIM #105830) syndromes are clinically distinct genetic disorders, both mapping to chromosome region 15q11-q13.

PWS is the most common genetic cause of obesity, owing to an involuntary urge to eat constantly coupled with a reduced need for calories. Additional non-specific symptoms are short stature, mental retardation, incomplete sexual development and behavioural problems. In infancy, PWS is characterised by severe hypotonia and feeding difficulties – both common conditions which make clinical diagnosis difficult.

AS is characterised by severe mental retardation, microcephaly, seizures, characteristic abnormal behaviours – including apparent happy demeanour and hand-flapping movements – facial appearance and severe speech limitations. Delayed onset of specific features means that clinical diagnosis is difficult in the first two to three years of life.

The incidence of each syndrome is approximately 1 in 15 000, but may be underestimated due to the difficulty of clinical diagnosis, with either relatively non-specific findings particularly in infancy, or clinical overlap with many other disorders.

Genetic diagnosis of Prader Willi and Angelman syndromes

Genetic testing for PWS and AS has become the standard diagnostic method since clinical criteria, though defined, are not always specific. Moreover the number of genetic tests performed for PWS and AS is significantly higher than the number of positively diagnosed cases.

However, the complexity of genetic testing for PWS and AS is itself compounded by the underlying atypical genetics – chromosome region 15q11-q13 contains an ‘imprinted region’, whereby genes from the chromosome pair are unequally expressed. The level of expression is determined by the parental origin of the chromosome. Imprinting of the genes within chromosome region 15q11-q13 is under control of an ‘imprinting centre’ which regulates gene expression through epigenetic changes including methylation. The genes associated with PWS are usually only expressed on the paternally-inherited chromosome 15 whilst the maternally-inherited genes are inactivated.

Conversely, the gene or genes associated with AS – including UBE3A – are usually only expressed on the maternally-inherited chromosome 15 whilst the paternally-inherited genes are inactivated. Loss of gene function can be due to a genetic deletion in the chromosome 15q11-q13 region, uniparental disomy – inheritance of both copies of a chromosome or part of a chromosome from only one parent – or an imprinting centre defect. AS can additionally result from a mutation in the UBE3A gene.

There are several testing methods for the cytogenetic or molecular diagnosis of PWS and AS, the most common being DNA-based methylation testing for abnormal methylation in the chromosome 15q11-q13 region. This method will detect more than 99% of PWS individuals and approximately 80% of AS individuals. Sequence analysis of the UBE3A gene will detect a further approximate 10% of individuals with AS. 

1st International Genetic Reference Panel for Prader Willi and Angelman Syndromes

The panel comprises six human genomic DNA samples to cover a range of Prader Willi and Angelman syndrome genetic defects. Samples are presented as 5 µg freeze dried genomic DNA in glass ampoules. The collaborative validation study data indicates that these materials are suitable for use in methylation-specific multiplex ligation-dependent probe amplification, methylation-specific PCR and UBE3A sequencing

Clinical Diagnosis

Genetic Defect

Angelman syndrome

maternal deletion

Angelman syndrome

UBE3A point mutation

Angelman syndrome

paternal uniparental disomy or imprinting centre defect

Prader Willi syndrome

paternal deletion

Prader Willi syndrome

maternal uniparental disomy

Prader Willi syndrome

paternal deletion 

                                 A Karyotype

                                                                                                                         


                                B Array CGH


Genotype confirmation of Prader Willi, paternal deletion material

The panel was validated in an international collaborative study and the genotypes confirmed by the use of methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), methylation-specific PCR (MS-PCR), UBE3A sequence analysis, Southern blotting, microsatellite analysis, methylation-sensitive PCR, DHPLC and methylation-specific melting analysis.

Reference

Boyle J et al. (2011) Establishment of the first WHO international genetic reference panel for Prader Willi and Angelman syndromes. Eur J Hum Genet. 19:857-64

How to order

To place an order please login to your account or sign up for a new account. 

For scientific enquiries contact the team at grmteam@nibsc.org.

Key Staff

Dr Ross Hawkins – Section Head
Dr Ravneet Bhuller
Mr Malcolm Hawkins 
Dr Leandro Lo Cascio
Mr Noble Ossai
Dr Pia Sanzone
Mr Miltiades Stylianou

Available standards

09/140: Prader Willi and Angelman Syndromes (WHO)

Other genomic reference materials 

Ordering genomic reference materials

Further information on ordering genomic reference materials from NIBSC. 

Contact us 

grmteam@nibsc.org

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap